Everest Medicines (HKEX: 1952.HK) ('Everest'), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialisation of innovative medicines and vaccines, announced on Sunday that it has named Sandra Zeng as its new chief medical officer and Rico Liang as its new chief product officer.

Zeng has over 20 years of experience in the oncology and immunology industries across diversified functions, including pharmaceutical discovery, development and medical affairs in US and China. She has most recently served as Global Development Program Lead in Hematology in Bristol Myers Squibb USA, and has served in various leadership positions in Celgene Corporation, Roche and Merck.

Liang has over two decades of experience in the pharmaceutical industry, largely in medical affairs, marketing and sales management and clinical operation. He has served as general manager of Greater China at Brii Biosciences and in various leadership positions in Gilead China, including as executive director. He has served in various positions in Roche, Novartis and Amgen.